{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:06:28Z","timestamp":1788444388601,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R61AI136002"],"award-info":[{"award-number":["R61AI136002"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI150358"],"award-info":[{"award-number":["R01AI150358"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11095-025-03969-2","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T23:22:19Z","timestamp":1762989739000},"page":"2185-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Next Generation 3D Printed Multipurpose Intravaginal Ring For Sustained Co-Delivery of Antiretroviral Drugs and A Contraceptive Hormone"],"prefix":"10.1007","volume":"42","author":[{"given":"Denali K.","family":"Dahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Janusziewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopali","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panita","family":"Maturavongsadit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5871","authenticated-orcid":false,"given":"S. Rahima","family":"Benhabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"3969_CR1","unstructured":"World Health Organization. 2024. https:\/\/www.who.int\/news\/item\/11-12-2024-over-1-in-5-adults-worldwide-has-a-genital-herpes-infection-who."},{"key":"3969_CR2","unstructured":"HIV and AIDS. 2025.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"3969_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.contraception.2015.09.002","volume":"93","author":"E Schelar","year":"2016","unstructured":"Schelar E, et al. Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products. Contraception. 2016;93:32\u201343.","journal-title":"Contraception"},{"key":"3969_CR4","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/S2214-109X(18)30029-9","volume":"6","author":"J Bearak","year":"2018","unstructured":"Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6:e380-9.","journal-title":"Lancet Glob Health"},{"issue":"s5","key":"3969_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/1471-0528.12842","volume":"121","author":"S Abdool Karim","year":"2014","unstructured":"Abdool Karim S, Baxter C, Frohlich J, Abdool Karim Q. The need for multipurpose prevention technologies in sub-Saharan Africa. BJOG: An International Journal of Obstetrics & Gynaecology. 2014;121(s5):27\u201334.","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"key":"3969_CR6","unstructured":"IMPT. MPT product development database.\u00a02024. Available at: http:\/\/mpts101.org\/mpt-database."},{"key":"3969_CR7","unstructured":"Organization, W.H. Multipurpose Prevention Technologies (MPTs). Sexual and reproductive health. 2021."},{"key":"3969_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","volume":"20","author":"EE Freeman","year":"2006","unstructured":"Freeman EE, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73\u201383.","journal-title":"AIDS"},{"key":"3969_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","volume":"17","author":"KJ Looker","year":"2017","unstructured":"Looker KJ, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17:1303\u201316.","journal-title":"Lancet Infect Dis"},{"key":"3969_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","volume":"20","author":"KJ Looker","year":"2020","unstructured":"Looker KJ, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020;20:240\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3969_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/QAD.0b013e32832e15e8","volume":"23","author":"JR Glynn","year":"2009","unstructured":"Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS. 2009;23:1595\u20138.","journal-title":"AIDS"},{"key":"3969_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/13625187.2018.1508650","volume":"23","author":"B Young Holt","year":"2018","unstructured":"Young Holt B, et al. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. Eur J Contracept Reprod Health Care. 2018;23:326\u201334.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"3969_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1471-0528.12913","volume":"121","author":"M Warren","year":"2014","unstructured":"Warren M. Condoms: the multipurpose prevention technologies that already exist. BJOG: An International Journal of Obstetrics & Gynaecology. 2014;121:9\u201311.","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"key":"3969_CR14","unstructured":"Imperative, R.I.W.s.G.H. TRIO General Research Brief: What End-Users Think About HIV Prevention Products and Multipurpose Prevention Technologies (MPT). 2020."},{"key":"3969_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/IJWH.S36282","volume":"4","author":"RK Malcolm","year":"2012","unstructured":"Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I. Vaginal rings for delivery of HIV microbicides. Int J Womens Health. 2012;4:595\u2013605.","journal-title":"Int J Womens Health"},{"key":"3969_CR16","unstructured":"Chinmaya Keshari Sahoo, P.K.N., Deepak Kumar Sarangi, Tanmaya, Keshari Sahoo4 Intra vaginal drug delivery system: an overview. Am J Adv Drug Deliv.\u00a02013."},{"key":"3969_CR17","doi-asserted-by":"crossref","unstructured":"Wieder, D.R., and Lynn Pattimakiel. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing\u00ae). Int J Womens Health. 2010; 2:401.","DOI":"10.2147\/IJWH.S6162"},{"issue":"6","key":"3969_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.contraception.2006.07.004","volume":"74","author":"H-J Ahrendt","year":"2006","unstructured":"Ahrendt H-J, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring,NuvaRing, compared with an oral contraceptive containing 30lgofethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74(6):451\u20137.","journal-title":"Contraception"},{"issue":"6","key":"3969_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/13625187.2017.1413179","volume":"22","author":"J Algorta","year":"2017","unstructured":"Algorta J, et al. Pharmacokinetic bioequivalence, safety and acceptability of Ornibel, a new polymer composition contraceptive vaginal ring (etonogestrel\/ethinylestradiol 11.00\/3.474 mg) compared with Nuvaring\u00ae (etonogestrel\/ ethinylestradiol 11.7\/2.7 mg). Eur J Contracept Reprod Health Care. 2017;22(6):429\u201338.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"3969_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy8030156","author":"JJ Virro","year":"2020","unstructured":"Virro JJ, et al. Long-lasting, patient-controlled, procedure-free contraception: a review of Annovera with a pharmacist perspective. Pharmacy. 2020. https:\/\/doi.org\/10.3390\/pharmacy8030156.","journal-title":"Pharmacy"},{"key":"3969_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118574","volume":"569","author":"YH Dallal Bashi","year":"2019","unstructured":"Dallal Bashi YH, et al. Towards a dapivirine and levonorgestrel multipurpose vaginal ring: investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. Int J Pharm. 2019;569:118574.","journal-title":"Int J Pharm"},{"key":"3969_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185946","volume":"12","author":"JM Smith","year":"2017","unstructured":"Smith JM, et al. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: pharmacokinetic evaluation in a macaque model. PLoS ONE. 2017;12:e0185946.","journal-title":"PLoS ONE"},{"key":"3969_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","volume":"39","author":"TJ Johnson","year":"2010","unstructured":"Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci. 2010;39:203\u201312.","journal-title":"Eur J Pharm Sci"},{"key":"3969_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jconrel.2012.08.033","volume":"163","author":"JT Clark","year":"2012","unstructured":"Clark JT, et al. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release. 2012;163:240\u20138.","journal-title":"J Control Release"},{"key":"3969_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088509","volume":"9","author":"JT Clark","year":"2014","unstructured":"Clark JT, et al. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS ONE. 2014;9:e88509.","journal-title":"PLoS ONE"},{"issue":"8","key":"3969_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/admt.202000261","volume":"5","author":"R Janusziewicz","year":"2020","unstructured":"Janusziewicz R, Mecham SJ, Olson KR, Benhabbour SR. Design and characterization of a novel series of geometrically complex intravaginal rings with digital light synthesis. Adv Mater Technol. 2020;5(8):1\u201316.","journal-title":"Adv Mater Technol"},{"key":"3969_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtchem.2022.100978","volume":"24","author":"R Janusziewicz","year":"2022","unstructured":"Janusziewicz R, et al. Fundamental investigation of sustained and controlled therapeutics release from 3D printed medical devices. Mater Today Chem. 2022;24:100978.","journal-title":"Mater Today Chem"},{"key":"3969_CR28","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1073\/pnas.1605271113","volume":"113","author":"R Janusziewicz","year":"2016","unstructured":"Janusziewicz R, Tumbleston JR, Quintanilla AL, Mecham SJ, Desimone JM. Layerless fabrication with continuous liquid interface production. Proc Natl Acad Sci U S A. 2016;113:11703\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3969_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jconrel.2024.10.059","volume":"376","author":"DK Dahl","year":"2024","unstructured":"Dahl DK, et al. Next-generation 3D printed multipurpose prevention intravaginal ring for prevention of HIV, HSV-2, and unintended pregnancy. J Control Release. 2024;376:1209\u201324.","journal-title":"J Control Release"},{"key":"3969_CR30","doi-asserted-by":"crossref","unstructured":"Isabella C. Young, P.S., Roopali Shrivastava, Rima Janusziewicz, Allison Thorson, Mackenzie L. Cottrell, Rani S. Sellers, Craig Sykes, Amanda Schauer, Dawn Little, Kristen Kelley, Angela D. M. Kashuba, David Katz, Richard B. Pyles, J. Gerardo Garcia-Lerma, Kathleen L. Vincent, James Smith, S. Rahima Benhabbour Next Generation 3D-Printed Intravaginal Ring for Prevention of HIV and Unintended Pregnancy. Biomater.\u00a02023;301:122260.","DOI":"10.1016\/j.biomaterials.2023.122260"},{"key":"3969_CR31","doi-asserted-by":"crossref","unstructured":"Rima Janusziewicz, R.S., Denali Dehal, Isabella Young, Milosz Bis, Ashlyn N. Whitesell, S. Rahima Benhabbour Fundamental investigation of sustained and controlled therapeutics release from 3D printed devices. Mater Today Chem\u00a024. 2022;100978:1\u201317.","DOI":"10.1016\/j.mtchem.2022.100978"},{"key":"3969_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.08.051","volume":"550","author":"DJ Murphy","year":"2018","unstructured":"Murphy DJ, et al. Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques. Int J Pharm. 2018;550:300\u20138.","journal-title":"Int J Pharm"},{"key":"3969_CR33","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1093\/jac\/dku160","volume":"69","author":"DJ Murphy","year":"2014","unstructured":"Murphy DJ, et al. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. J Antimicrob Chemother. 2014;69:2477\u201388.","journal-title":"J Antimicrob Chemother"},{"key":"3969_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/QAI.0b013e3181acb536","volume":"51","author":"A Nel","year":"2009","unstructured":"Nel A, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. JAIDS J Acquir Immune Defic Syndr. 2009;51:416\u201323.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"3969_CR35","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","volume":"8","author":"A Nel","year":"2021","unstructured":"Nel A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8:e77\u201386.","journal-title":"Lancet HIV"},{"key":"3969_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/aid.2008.0184","volume":"25","author":"J Romano","year":"2009","unstructured":"Romano J, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009;25:483\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3969_CR37","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.antiviral.2013.09.025","volume":"100","author":"B Devlin","year":"2013","unstructured":"Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antivir Res. 2013;100:S3-8.","journal-title":"Antivir Res"},{"key":"3969_CR38","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133\u201343.","journal-title":"N Engl J Med"},{"key":"3969_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-021-03205-z","author":"AJ Mayo","year":"2021","unstructured":"Mayo AJ, et al. Acceptability of the dapivirine vaginal ring for HIV-1 prevention and association with adherence in a phase III trial. AIDS Behav. 2021. https:\/\/doi.org\/10.1007\/s10461-021-03205-z.","journal-title":"AIDS Behav"},{"key":"3969_CR40","first-page":"S39","volume":"100","author":"DR Friend","year":"2013","unstructured":"Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: Products in development. 2013;100:S39\u201347.","journal-title":"Multipurpose prevention technologies: Products in development"},{"key":"3969_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0010-7824(81)90002-0","volume":"24","author":"TM Jackanicz","year":"1981","unstructured":"Jackanicz TM. Levonorgestrel and estradiol release from an improved contraceptive vaginal ring. Contraception. 1981;24:323\u201339.","journal-title":"Contraception"},{"key":"3969_CR42","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1039\/C9MD00233B","volume":"10","author":"H Ruebsamen-Schaeff","year":"2019","unstructured":"Ruebsamen-Schaeff H, Buschmann H. Different solid forms for optimizing route of administration of the herpes drug Pritelivir. Medchemcomm. 2019;10:1867\u201370.","journal-title":"Medchemcomm"},{"key":"3969_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMoa1301150","volume":"370","author":"A Wald","year":"2014","unstructured":"Wald A, et al. Helicase\u2013primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370:201\u201310.","journal-title":"N Engl J Med"},{"key":"3969_CR44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1128\/AAC.05662-11","volume":"56","author":"JA Moss","year":"2012","unstructured":"Moss JA, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother. 2012;56:875\u201382.","journal-title":"Antimicrob Agents Chemother"},{"key":"3969_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.antiviral.2013.08.024","volume":"100","author":"HJ Field","year":"2013","unstructured":"Field HJ, et al. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase\u2013primase inhibitor pritelivir. Antivir Res. 2013;100:297\u20139.","journal-title":"Antivir Res"},{"key":"3969_CR46","unstructured":"FDA Q3C-Tables and List Guidance for Industry. Food and Drug Administration. 2017."},{"key":"3969_CR47","doi-asserted-by":"crossref","unstructured":"P. Liu, O.D.W., J. Laru, T. Heikkila, B. van Veen, J. Kiesvaara, J. Hirvonen, L. Peltonen, T. Laaksonen Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions. AAPS PharmSciTech. 2013;14(2):748\u2013756.","DOI":"10.1208\/s12249-013-9960-2"},{"key":"3969_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/admt.202000261","volume":"5","author":"R Janusziewicz","year":"2020","unstructured":"Janusziewicz R, Mecham SJ, Olson KR, Benhabbour SR. Design and characterization of a novel series of geometrically complex intravaginal rings with digital light synthesis. Adv Mater Technol. 2020;5:2000261.","journal-title":"Adv Mater Technol"},{"key":"3969_CR49","doi-asserted-by":"crossref","unstructured":"Radomsky, M.L.W., K. J.; Cone, R. A.; Saltzman, W. M. Controlled vaginal delivery of antibodies in the mouse. Biol Reprod. 1992;47(1):133\u2013140.","DOI":"10.1095\/biolreprod47.1.133"},{"key":"3969_CR50","doi-asserted-by":"crossref","unstructured":"Tumbleston, J.R.S., D.; Ermoshkin, N.; Janusziewicz, R.; Johnson, A. R.; Kelly, D.; Chen, K.; Pinschmidt, R.; Rolland, J. P.; Ermoshkin, A.; Samulski, E. T.; DeSimone, J. M. Additive manufacturing. Continuous liquid interface production of 3D objects. Sci.\u00a02015;347:1349\u20131352.","DOI":"10.1126\/science.aaa2397"},{"key":"3969_CR51","doi-asserted-by":"crossref","unstructured":"Janusziewicz, R.T., J. R.; Quintanilla, A. L.; Mecham, S. J.; DeSimone, J. M. Layerless fabrication with continuous liquid interface production. Proc Natl Acad Sci. 2016;113(42):11703\u201311708.","DOI":"10.1073\/pnas.1605271113"},{"key":"3969_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.mtchem.2022.100978","volume":"24","author":"R Janusziewicz","year":"2022","unstructured":"Janusziewicz R, et al. Fundamental investigation of sustained and controlled therapeutics release from 3D printed medical devices. Materials Today Chemistry. 2022;24:17.","journal-title":"Materials Today Chemistry"},{"key":"3969_CR53","unstructured":"FDA FDA.gov; 2017."},{"key":"3969_CR54","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.antiviral.2013.09.025","volume":"100","author":"B Devlin","year":"2013","unstructured":"Devlin B, et al. Development of dapivirine vaginal ring for HIV prevention. Antivir Res. 2013;100:S3\u20138.","journal-title":"Antivir Res"},{"key":"3969_CR55","unstructured":"Agency, E.M., Summary of Product Characteristics: Dapivirine Vaginal Ring 25mg. 2020."},{"issue":"22","key":"3969_CR56","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med"},{"key":"3969_CR57","doi-asserted-by":"crossref","unstructured":"M.-H. Schultze-Mosgau, K.W., R. Nave, S. Klein, J. Kraetzschmar, T. Rautenberg, H. Schmitz, B. Rohde Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. Hum Reprod\u00a02016;1(8): p. 1713\u20131722.","DOI":"10.1093\/humrep\/dew145"},{"issue":"2","key":"3969_CR58","first-page":"105","volume":"41","author":"S Koetsawang","year":"1990","unstructured":"Koetsawang S, et al. Microdose intravaginal levonorgestrel contraception: A multicentre clinical trial: I. Contraceptive efficacy and side effects Contraception. 1990;41(2):105\u201324.","journal-title":"Contraceptive efficacy and side effects Contraception"},{"issue":"5","key":"3969_CR59","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0010-7824(85)90016-2","volume":"32","author":"B Xiao","year":"1985","unstructured":"Xiao B, Zhang X, Feng D. Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel. Contraception. 1985;32(5):455\u201371.","journal-title":"Contraception"},{"issue":"23","key":"3969_CR60","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1001\/jama.2016.18189","volume":"316","author":"A Wald","year":"2016","unstructured":"Wald A, et al. Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences. JAMA. 2016;316:2495.","journal-title":"JAMA"},{"key":"3969_CR61","doi-asserted-by":"publisher","DOI":"10.1177\/09564624211006568","author":"L Cannon","year":"2021","unstructured":"Cannon L, Tholouli E, Ward C, Farooq H, Kingston M. Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2. Int J STD AIDS. 2021. https:\/\/doi.org\/10.1177\/09564624211006568.","journal-title":"Int J STD AIDS"},{"key":"3969_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101391","volume":"55","author":"NJ Giannasca","year":"2020","unstructured":"Giannasca NJ, Suon JS, Evans AC, Margulies BJ. Matrix-based controlled release delivery of acyclovir from poly-(ethylene co-vinyl acetate) rings. J Drug Deliv Sci Technol. 2020;55:101391.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3969_CR63","doi-asserted-by":"crossref","unstructured":"John A. Moss, A.M.M., Thomas J. Smith, Sean Kennedy, Etana Kopin, & Cali Nguyen, J.G., Irina Butkyavichene, Kathleen L. Vincent, Massoud Motamedi, David R. Friend, Meredith R. Clark, Marc M. Baum Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring. Antimicrob Agents Chemother.\u00a02011;875\u2013 882.","DOI":"10.1128\/AAC.05662-11"},{"key":"3969_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","volume":"59","author":"DH Owen","year":"1999","unstructured":"Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999;59:91\u20135.","journal-title":"Contraception"},{"key":"3969_CR65","unstructured":"WHO Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. World Health Organ Tech Rep Ser. 2009;No. 953."},{"key":"3969_CR66","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jconrel.2024.10.059","volume":"376","author":"DK Dahl","year":"2024","unstructured":"Dahl DK, et al. Next-generation 3D printed multipurpose prevention intravaginal ring for prevention of HIV, HSV-2, and unintended pregnancy. J Control Release. 2024;376:1209\u201324.","journal-title":"J Control Release"},{"key":"3969_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16081030","author":"IC Young","year":"2024","unstructured":"Young IC, et al. Next-generation contraceptive intravaginal ring: comparison of Etonogestrel and Ethinyl Estradiol in vitro and in vivo release from 3D-printed intravaginal ring and NuvaRing. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16081030.","journal-title":"Pharmaceutics"},{"key":"3969_CR68","unstructured":"Agency, E.M. Summary of Product Characteristics: Dapivirine Vaginal Ring 25mg. 2020."},{"key":"3969_CR69","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121\u201332.","journal-title":"N Engl J Med"},{"key":"3969_CR70","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/humrep\/dew145","volume":"31","author":"M-H Schultze-Mosgau","year":"2016","unstructured":"Schultze-Mosgau M-H, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a phase 1 randomized controlled trial. Hum Reprod. 2016;31:1713\u201322.","journal-title":"Hum Reprod"},{"key":"3969_CR71","first-page":"105","volume":"41","author":"S Koetsawang","year":"1990","unstructured":"Koetsawang S, et al. Microdose intravaginal levonorgestrel contraception: A multicentre clinical trial: I. Contraceptive efficacy and side effects Contraception. 1990;41:105\u201324.","journal-title":"Contraceptive efficacy and side effects Contraception"},{"key":"3969_CR72","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0010-7824(85)90016-2","volume":"32","author":"B Xiao","year":"1985","unstructured":"Xiao B, Zhang X, Feng D. Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel. Contraception. 1985;32:455\u201371.","journal-title":"Contraception"},{"key":"3969_CR73","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ijpharm.2016.07.051","volume":"511","author":"P Boyd","year":"2016","unstructured":"Boyd P, et al. Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. Int J Pharm. 2016;511:619\u201329.","journal-title":"Int J Pharm"},{"key":"3969_CR74","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2016.02.020","volume":"226","author":"DJ Murphy","year":"2016","unstructured":"Murphy DJ, et al. Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device. J Control Release. 2016;226:138\u201347.","journal-title":"J Control Release"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03969-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:02:58Z","timestamp":1768932178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03969-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3969"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03969-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.R.B and R.J are inventors on a patent describing geometrically complex intravaginal rings and their methods of fabrication and a patent application describing the post-fabrication drug loading process; and are the Founders of Anelleo, Inc., which has licensed these patents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}